1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Disponível em: www.ginasthma.org . Acesso em: 27/08/2019.

2. Carr TF, Bleecker E. Asthma heterogeneity and severity. World Allergy Organ J. 2016;9(1):41.

3. Ullmann N, Mirra V, Di Marco A, Pavone M, Porcaro F, Negro V, et al. Asthma: Differential Diagnosis and Comorbidities. Front Pediatr. 2018;6:276.

4. Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemière C, et al. Reevaluation of diagnosis in adults with physiciandiagnosed asthma. JAMA. 2017;317(3):269‑79.

5. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-73.

6. FitzGerald JM, Lemiere C, Lougheed MD, Ducharme FM, Dell SD, Ramsey C, et al. Recognition and management of severe asthma: A Canadian Thoracic Society position statement, Can J Respi Crit Care Sleep Med. 2017;1:199-221.

7. Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126(5):926-38.

8. Chung KF, Wenzel S, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2018 Jul 27;52(1). pii:1352020. doi: 10.1183/13993003.52020-2013.

9. Souza-Machado A, Cavalcanti M, Cruz AA. Má percepção da limitação aos fluxos aéreos em pacientes com asma moderada a grave. J Bras Pneumol. 2001;27(4):185-92.

10. Fernandes AGO, Souza-Machado C, Coelho RCP. Fatores de risco de morte em portadores de asma grave J Bras Pneumol. 2014;40(4):364‑72.

11. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902‑7.

12. Boulet LP, Boulet V, Milot J. How should we quantify asthma control? A proposal. Chest. 2002;122:2217‑23.

13. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: A survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59-65.

14. LeBlanc A, Robichaud P, Lacasse Y, Boulet LP. Quantification of asthma control: validation of the Asthma Control Scoring System. Allergy. 2007;62(2):120-5.

15. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol. 2007;119(4):817-25.

16. Kim H, Ellis AK, Fischer D, Noseworthy M, Olivenstein R, Chapman KR, et al. Asthma biomarkers in the age of biologics. Allergy Asthma Clin Immunol. 2017;13:48.

17. Korn SL, Both J, Jung M, Hübner M, Taube C, Buhl R. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol. 2011;107(6):474-9.

18. Roxo JPF, Ponte EV, Ramos DCB, Pimentel L, D'Oliveira Jr A, Cruz AA. Validação do Teste de Controle da Asma em português para uso no Brasil: validation for use in Brazil. J Bras Pneumol. 2010;36(2):159‑66.

19. Liu AH, Zeiger RS, Sorkness CA, Ostrom NK, Chipps BE, Rosa K, et al. The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma. J Allergy Clin Immunol. 2010;126(2):267‑73.

20. Oliveira SG, Sarria EE, Roncada C, Stein RT, Pitrez PM, Mattiello R. Validation of the Brazilian version of the childhood asthma control test (c-ACT). Pediatr Pulmonol. 2016;51(4):358-63.

21. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'wellcontrolled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med. 2006;100:616‑21.

22. Leite M, Ponte EV, Petroni J, D'Oliveira Jr A, Pizzichini E, Cruz AA. Avaliação do questionário de controle da asma validado para uso no Brasil. J Bras Pneumol. 2008:34(10):756‑63.

23. Skinner EA, Diette GB, Algatt-Bergstrom PJ, Nguyen TT, Clark RD, Markson LE, et al. The Asthma Therapy Assessment Questionnaire (ATAQ) for children and adolescents. Dis Manag. 2004;7(4):305‑13.

24. Tavares MGS, Pizzichini MMM, Steidle LJM, Nazário NO, Rocha CC, Perraro MC, et al . The Asthma Control Scoring System: translation and cross-cultural adaptation for use in Brazil. J Bras Pneumol. 2010;36(6):683-92.

25. Global initiative for asthma - GINA. Difficult-to-treatment severe asthma in adolescents and adult patients. Diagnosis and management 2019. Disponível em: https://ginasthma.org/wpcontent/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf. Acesso em maio de 2019.

26. Chung KF. Managing severe asthma in adults: lessons from the ERS/ATS guidelines. Curr Opin Pulm Med. 2015;21(1):8-15.

27. Tay TR, Hew M. Comorbid "treatable traits" in difficult asthma: Current evidence and clinical evaluation. Allergy. 2018;73(7):1369‑82.

28. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66(10):910-7.

29. von Bülow A, Backer V, Bodtger U, Søes-Petersen NU, Vest S, Steffensen I, et al. Differentiation of adult severe asthma from difficult-to-treat asthma – Outcomes of a systematic assessment protocol. Respir Med. 2018;145:41-7.

30. von Bülow A, Backer V, Bodtger U, Søes-Petersen NU, Assing KD, Skjold T, et al. The level of diagnostic assessment in severe asthma: A Nationwide real-life study. Respir Med. 2017;124:21‑9.

31. Levy ML, Quanjer PH, Booker R, Cooper BG, Holmes S, Small I; General Practice Airways Group. Diagnostic spirometry in primary care: Proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations: a General Practice Airways Group (GPIAG)1 document, in association with the Association for Respiratory Technology & Physiology (ARTP)2 and Education for Health3 1 www.gpiag.org 2 www.artp.org 3 www.educationforhealth.org.uk. Prim Care Respir J. 2009;18(3):130‑47.

32. Radhakrishna N, Tay TR, Hore-Lacy F, Hoy R, Dabscheck E, Hew M. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med. 2016;117:166‑73.

33. Freitas Ferreira E, Pascoal A, Silva P, Lourenço O, Valente S, Valente MJ, et al. Inhaler training and asthma knowledge are associated with a higher proportion of patients with correct inhaler technique in young but not in elderly asthmatic patients. J Asthma. 2019;27:1‑11.

34. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):30‑8.

35. Kocks JWH, Chrystyn H, van der Palen J, Thomas M, Yates L, Landis SH, et al. Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD. NPJ Prim Care Respir Med. 2018;28:43.

36. Giraud V, Roche N. Misuse of corticosteroid metered dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002;19:246‑51.

37. Ho SF, O’Mahony MS, Steward JA, Breay P, Burr ML. Inhaler technique in older people in the community. Age Ageing. 2004;33:185‑8.

38. Coelho ACC, Souza-Machado A, Leite M, Almeida P, Castro L, Cruz CS, et al. Use of inhaler devices and asthma control in severe asthma patients at a referral center in the city of Salvador, Brazil. J Bras Pneumol. 2011;37:720‑8.

39. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593‑604.

40. Bosnic-Anticevich SZ, Sinha H, So S, Reddel HK. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. J Asthma. 2010;47:251‑6.

41. Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, Bradding P, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012;67(8):751‑3.

42. Axelsson M, Ekerljung L, Lundbäck B. The Significance of Asthma Follow-Up Consultations for Adherence to Asthma Medication, Asthma Medication Beliefs, and Asthma Control. Nurs Res Pract. 2015:139070. doi: 10.1155/2015/139070.

43. Lin J, Yang D, Huang M, Zhang Y, Chen P, Cai S, et al. Chinese expert consensus on diagnosis and management of severe asthma. J Thorac Dis. 2018;10(12):7020-44.

44. Jeminiwa R, Hohmann L, Qian J, Garza K, Hansen R, Fox BI. Impact of eHealth on medication adherence among patients with asthma: A systematic review and meta-analysis. Respir Med. 2019;149:59‑68.

45. Thomson NC, Chaudhuri R, Heaney LG, Bucknall C, Niven RM, Brightling CE, et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J Allergy Clin Immunol. 2013;131(4):1008‑16.

46. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficultto-treat asthma. Ann Allergy Asthma Immunol. 2004;92(1):32-9.

47. Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM. British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax. 2010;65:787-94.

48. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the crosssectional world health survey. BMC Public Health. 2012;12:204. doi: 10.1186/1471-2458-12-204.

49. Hoy RF, Brims F. Occupational lung diseases in Australia. Med J Aust. 2017;207(10):443‑8.

50. Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse Respiratory Effect of Acute ß-Blocker Exposure in Asthma. Chest. 2014;145(4),779‑86.

51. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005;116:970-5.

52. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676-81.

53. Gherasim A, Dao A, Bernstein JA. Confounders of severe asthma: diagnoses to consider when asthma symptoms persist despite optimal therapy. World Allergy Organ J. 2018;14;11(1):29.

54. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315-23.

55. Hekking PP, Amelink M, Wener RR, Bouvy ML, Bel EH. Comorbidities in Difficult-to-Control Asthma. J Allergy Clin Immunol Pract. 2018;6(1):108‑13.

56. Tay TR, Radhakrishna N, Hore-Lacy F, Smith C, Hoy R, Dabscheck E, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21(8):1384‑90.

57. Bousquet J, Schünemann HJ, Samolinski B, Demoly P, BaenaCagnani CE, Bachert C, ET AL. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs.J Allergy Clin Immunol. 2012;130(5):1049-62.

58. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308-21.

59. Novelli F, Bacci E, Latorre M, Seccia V, Bartoli ML, Cianchetti S, et al. Comorbidities are associated with different features of severe asthma. Clin Mol Allergy. 2018;16:25.

60. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405‑13.

61. Gibson P, Henry R, Coughlan J. Gastro-oesophageal reflux treatment for asthma in adults and children (Review). Cochrane Database Syst Rev. 2003;(2):CD001496.

62. Hopper AD. Improving the diagnosis and management of GORD in adults. Practitioner. 2015;259(1781):27-32.

63. Morris MJ, Christopher KL. Diagnostic criteria for the classification of vocal cord dysfunction. Chest. 2010;138(5):1213‑23.

64. Yelken K, Yilmaz A, Guven M, Eyibilen A, Aladag I. Paradoxical vocal fold motion dysfunction in asthma patients. Respirology. 2009;14(5):729‑33.

65. Fretzayas A, Moustaki M, Loukou I, Douros K. Differentiating vocal cord dysfunction from asthma. J Asthma Allergy. 2017;10:277‑83.

66. Davies SE, Bishopp A, Wharton S, Turner AM, Mansur AH. The association between asthma and obstructive sleep apnea (OSA): A systematic review. J Asthma. 2019 Feb;56(2):118-29.

67. Kenn K, Balkissoon R. Asthma: Vocal Cord Dysfunction (VCD) and other Dysfunctional Breathing Disorders. Sem Respir Crit Care Med. 2004;33(06):595‑605.

68. Ritz T, Rosenfield D, Meuret AE, Bobb C, Steptoe A. Hyperventilation symptoms are linked to a lower perceived health in asthma patients. Ann Behav Med. 2008;35(1):97-104.

69. van Veen IH, ten Brinke A, Sterk PJ, Rabe KF, Bel EH. Airway inflammation in obese and nonobese patients with difficult-to-treat asthma. Allergy. 2008;63:570‑4.

70. Ciprandi G, Schiavetti I, Rindone E, Ricciardolo FLM. The impact of anxiety and depression on outpatients with asthma. Ann Allergy Asthma Immunol. 2015;115(5):408-14.

71. McDonald VM, Hiles SA, Godbout K, Harvey ES, Marks GB, Hew M, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019 Jan;24(1):37‑47.

72. Global initiative for lung chronic disease - GOLD. Global strategy for prevention, diagnosis and management of COPD. Updated

2019. Disponível em: https://goldcopd.org/gold-reports/. Acesso em: março/2019.

73. Boulet LP, Boulay MÈ, Dérival JL, Milot J, Lepage J, Bilodeau L, et al. Asthma-COPD Overlap Phenotypes and Smoking: Comparative features of asthma in smoking or non-smoking patients with an incomplete reversibility of airway obstruction. COPD. 2018;15(2):130‑8.

74. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43:850-73.

75. Gupta S, Siddiqui S, Haldar P, Raj JV, Entwisle JJ, Wardlaw AJ, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest. 2009;136:1521‑8.

76. Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Int Med. 2015;26:545‑53.

77. Fitzpatrick AM, Moore WC. Severe Asthma Phenotypes - How should they guide evaluation and treatment? J Allergy Clin Immunol Pract. 2017;5:901-8.

78. Charriot J, Vachier I, Halimi L, Gamez AS, Boissin C, Salama M, et al. Future treatment for asthma. Eur Respir Rev. 2016;25:77-92.

79. Tabatabaian F, Ledford DK, Casale TB. Biologic and New Therapies in Asthma. Immunol Allergy Clin N Am. 2017;37:329‑43.

80. Carr TF, Kraft M. Management of Severe Asthma before Referral to the Severe Asthma Specialist. J Allergy Clin Immunol Pract. 2017;5:877-86.

81. Pepper AN, Renz H, Casale TB, Garn H. Biologic Therapy and Novel Molecular Targets of Severe Asthma. J Allergy Clin Immunol Pract. 2017;5:909-16.

82. Katial CRK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. J Allergy Clin Immunol Pract. 2017;5:S1-S14.

83. The BTS/SIGN Guideline for the management of asthma 2016. [site na internet]. Disponível em: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthmaguideline-2016/. Acesso em: 25/03/2019.

84. Zervas E, Samitas K, Papaioannou AI, et al. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res.

2018 Mar 6;4(1). pii: 00125-2017.

85. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165(10):1377‑83.

86. Skoner DP. Inhaled corticosteroids. Effects on growth and bone health. Ann Allergy Asthma Immunol. 2016;117(6):595-600.

87. Carr WW, Szefler SJ. Inhaled corticosteroids: Ocular safety and the hypothalamic-pituitary-adrenal axis. Ann Allergy Asthma Immunol. 2016;117(6):589-94.

88. Kew KM, Dahri K. Long-actingmuscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No.: CD011721.

89. Rodrigo GJ, Neffen H. Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review. Pediatr Allergy Immunol. 2017;28(6):573‑8.

90. Szefler SJ, Murphy K, Harper T 3rd, Boner A, Laki I, Engel M, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017;140(5):1277‑87.

91. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-90.

92. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309-16.

93. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumabinduced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004;114(3):527‑30.

94. Chan MA, Gigliotti NM, Dotson AL, Rosenwasser LJ. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy. 2013;3(1):29.

95. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476-85.

96. Carvalho-Pinto RM, Agondi RC, Giavina-Bianchi P, Cukier A, Stelmach R. Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control. J Bras Pneumol. 2017;43(6):487-9.

97. Karpel J, Massanari M, Geba GP, Kianifard F, Inhaber N, Zeldin RK. Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010;105(6):465-70.

98. Bhutani M, Yang WH, Hébert J, de Takacsy F, Stril JL. The real-world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. PLoS One. 2017;12(8):e0183869.

99. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med. 2009;103(11):1633-42.

100. Humbert M, Taillé C, Mala L, Le Gros V, Just J, Molimard M, et al. Omalizumabe effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018 May 10;51(5). pii: 1702523.

101. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60(3):302-8.

102. Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191.

103. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559.

104. Pitrez PM, de Souza RG, Roncada C, Heinzmann-Filho JP, Santos G, Pinto LA, et al. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: A real-life study. Pediatr Pulmonol. 2017;52(11):1408-13.

105. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-11.

106. Casale TB, Chipps BE, Rosén K, Trzaskoma B, Haselkorn T, Omachi TA, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490‑7.

107. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007;120(6):1378-81.

108. Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective RealWorld Study. J Allergy Clin Immunol Pract. 2019;7(1):156‑64.

109. Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, Fox H, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37(2):197-207.

110. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007;144(2):155-8.

111. Rambasek T, Kavuru MS. Omalizumab dosing via the recommended card versus use of the published formula. J Allergy Clin Immunol. 2006;117(3):708-9.

112. Menzies-Gow A, Robinson DS. Eosinophils, eosinophilic cytokines (interleukin-5), and antieosinophilic therapy in asthma. Curr Opin Pulm Med. 2002;8:33-8.

113. Robinson DS, Ying S, Bentley AM, Meng Q, North J, Durham SR, et al. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J Allergy Clin Immunol. 1993;92:397-403.

114. Nucala (mepolizumabe) - Nova indicação. Disponível em: http://portal.anvisa.gov.br/informacoes-tecnicas13?p_p_id=101_INSTANCE_WvKKx2fhdjM2&p_p_col_id=column2&p_p_col_pos=1&p_p_col_count=2&_101_INSTANCE_WvKKx2fhdjM2_groupId=219201&_101_INSTANCE_WvKKx2fhdjM2_urlTitle=nucala-mepolizumabe-&_101_INSTANCE_WvKKx2fhdjM2_struts_action=%2Fasset_publisher%2Fview_content&_101_INSTANCE_WvKKx2fhdjM2_assetEntryId=5584341&_101_INSTANCE_WvKKx2fhdjM2_type=content. Acesso em agosto de 2019.

115. Smith DA, Minthorn EA, Beerahee M, Carolina N. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-Interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011;50:215-27.

116. Tsukamoto N, Takahashi N, Itoh H, Pouliquen I. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. Clin Pharmacol Drug Dev. 2016;5:102-8.

117. Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53:1015-27.

118. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199-204.

119. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.

120. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (London, England). 2012;380:651-9.

121. Harrison T, Canonica GW, Gemzoe K, Maxwell A, Yang S, Joksaite S, et al. Effectiveness and safety in real-world clinical practice: the REALITI-A study. ERS International Congress 2019, Madrid, Abs-2104.

122. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-207.

123. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, openlabel, Phase IIIb study. Clin Ther. 2016:1-14.

124. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-97.

125. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549‑56.

126. Brusselle G, Germinaro M, Weiss S, Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39‑45.

127. FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51-64.

128. Koike M, Nakamura K, Furuya A, Iida A, Anazawa H, Takatsu K, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies. 2009;18(1‑2):17‑27.

129. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell- mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344‑53.

130. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;375:2448-58.

131. Bleeker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ß-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115-27.

132. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128-41.

133. FitzGerald JM, Bleeker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6:51-64.

134. Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7:46‑59.

135. Khorasanizadeh M, Eskian M, Assa'ad AH, Camargo CA Jr, Rezaei N. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma. Int Rev Immunol. 2016;35(4):294-311.

136. Busse WW. Biological treatments for severe asthma: A major advance in asthma care. Allergol Int. 2019 Apr;68(2):158-66.

137. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355e66.

138. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799e810.

139. Henriksen DP, Bodtger U, Sidenius K, Maltbaek N, Pedersen L, Madsen H, et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097.

140. Pérez de Llano LA, Cosío BG, Domingo C, Urrutia I, Bobolea I, Valero A, et al. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. J Allergy Clin Immunol Pract. 2019 Jan 21. pii: S2213-2198(19)30069-8.

141. Walsh GM. Dupilumab utility in difficult-to-treat asthma. Immunotherapy. 2019;11(4):261-4.

142. Sulaiman I, Lim JCW, Soo HL, Stanslas J. Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation. Pulm Pharmacol Ther. 2016;40:52‑68.

143. Take Action With DUPIXENT® (dupilumab). Disponível em: https://www.dupixent.com/ . Acesso em: junho/2019.

144. Wu AY, Sur S, Grant JA, Tripple JW. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma. Curr Opin Allergy Clin Immunol. 2019;19(1):30-7.

145. Carvalho VO, Solé D, Antunes AA, Bau AEK, Kuschnir FC, Mallozi MC, et al. Guia prático de atualização em dermatite atópica - Parte II: abordagem terapêutica. Posicionamento conjunto da Associação Brasileira de Alergia e Imunologia e da Sociedade Brasileira de Pediatria. Arq Asma Alerg Imunol. 2017;1(2):157‑82.

146. Zayed Y, Kheiri B, Banifadel M, Hicks M, Aburahma A, Hamid K, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2018 Oct 1:1-10.

147. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12:99‑106.

148. O’Dwyer DN, Moore BB. The role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci. 2017;74:4305‑14.

149. Matsumoto H. Serum periostin: a novel biomarker for asthma management. Allergol Int. 2014;63:153‑60.

150. Li H, Wang K, Huang H, Cheng W, Liu X. A meta-analysis of antiinterleukin-13 monoclonal antibodies for uncontrolled asthma. PLoS ONE. 14(1): e0211790.

151. Liu Y, Zhang S, Chen R, Wei J, Guan G, Zhou M, et al. Metaanalysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma. Allergy Asthma Proc. 2018;39(5):332‑7.

152. Steinke JW. Anti-interleukin-4 therapy. Immunol Allergy Clin North Am. 2004;24:599-614.

153. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11:958-72.

154. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017;377(10):936‑46.

155. Kao CC, Parulekar AD. Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date. J Asthma Allergy. 2019;12:1-5.

156. Bateman ED, Guerreros AG, Brockhaus F, Holzhauer B, Pethe A, Kay RA, et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J. 2017;50(2). pii: 1700670.

157. Kuna P, Bjermer L, Tornling G. Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma. Drug Des Devel Ther. 2016;10:2759‑70.

158. Zhu L, Ciaccio CE, Casala TB. Potential new targets for drug development in severe asthma. World Allergy Organ J. 2018;11(1):30.